You are about to leave for a 3rd party website 

The Medical Information website is a dedicated and secure portal to address health care professionals’ clinical or scientific questions related to Abbott Diabetes Care products. This website should not be shared with patients or non health care professionals. When submitting your inquiry, please select the global region where you reside.   

Do you wish to continue and leave this site?

Congress Abstracts

  • In adult patients with Type 1 diabetes, switching from real-time CGM (rtCGM) to intermittently-scanned CGM (isCGM) was associated with a signficant reduction in HbA1c that was sustained for up to 24 months.
  • Among Medicaid beneficiaries with Type 2 diabetes treated with basal insulin in the USA, the acquisiton of continuous glucose monitoring (CGM) was associated with significant improvements in hospitlizations, emergency department visits, as well as outpatient visits when comparing pre- and post-CGM periods.
  • Among Medicaid beneficiaries with Type 2 diabetes treated with multiple daily injections of insulin in the USA, the acquisiton of continuous glucose monitoring (CGM) was associated with significant improvements in hospitalizations, emergency department visits, as well as outpatient visits when comparing pre- and post-CGM periods.
  • In people with Type 2 diabetes with elevated HbA1c on prior GLP-1 RA therapy, the acquisition of FreeStyle Libre was associated with a significant reduction in HbA1c, irrespective of GLP-1 RA duration, GLP-1 RA type, or insulin therapy type.
  • In people with Type 2 diabetes with elevated HbA1c, the initiation of GLP-1 RA therapy and FreeStyle Libre was associated with a significant reduction in HbA1c compared to those initiating GLP-1 RA therapy alone.
  • At a willingness-to-pay threshold of $100,000 (USD) per quality adjusted life years (QALY) gained, the addition of FreeStyle Libre in people with Type 2 diabetes on GLP-1 RA therapy led to higher costs but more QALY gained compared to initiating GLP-1 RA therapy alone. 
  • In both non-hispanic white and black children and adults with Type 1 diabetes, the personalized estimated average glucose (peAG) using each individual's personal glycation ratio (PGR) demonstrated a more accurate estimate of average glycemia dervied from HbA1c compared to the estimated average glucose (eAG). 
  • A novel approach for evaluating red blood cell (RBC) glucose uptake demonstrated a large variation in glucose uptake across donor samples, with samples from donors of black ancestry demonstrating higher mean uptake than those with white ancestry.
  • Among 4,082 people with Type 1 or Type 2 diabetes using rapid-acting insulin, data from CGM and connected insulin pens suggests that glucose monitoring behavior is more predictive of overall glucose control than dosing behavior.
  • In a retrospective analysis of data from Bigfoot Unity Management System from users with Type 1 and 2 diabetes, CGM data availabilty of less than 70% did not show substantiatlly higher average HbA1c estimation errors when compared with GMI.
  • Retrospective data obtained from users with Type 1 and 2 diabetes using the Bigfoot Unity Management System for MDI demonstrated an association between changes to insulin therapy settings and improved CGM-derived outcomes.
  • Minimum Morning Glucose (MMG), a novel CGM-derived metric for estimating fasting blood glucose, may serve as a useful tool for guiding long-acting insulin dose titation in individuals with Type 1 and 2 diabetes.
  • Clinically significant A1C and AG-derived A1C discordance is common, particularly in Black individuals. Personalized A1C addresses this discrepancy potentially improving clinical management in diabetes and reducing health disparities.
  • People with T2DM not using insulin showed large, clinically significant improvements in CGM metrics and HbA1c when using either FSL CGM alone or FSL CGM plus a food logging application.
  • A subgroup analysis of the RELIEF study suggests that use of the FSL is associated with reduced hospital admissions for ADEs in people with T2DM treated with oral insulin-secretagogue drugs without insulin. Results suggest FSL may help support treatment optimization and reduce treatment inertia.
  • Compared to pre-FSL use, patients using FSL with type 2 diabetes treated with SU/meglitinides had lower healthcare utilization. Further research should assess the financial and patient impact of these event reductions.
  • A retrospective cohort study shows that frequent use of FSL plays a pivotal role in glucose management among people with T2D treated with basal insulin and GLP-1 RAs, where consistent FSL use is associated with sustained glycemic control, and inconsistent FSL use is associated with worsened glycemic outcomes.
  • After FreeStyle Libre adoption, HbA1c was statistically significantly improved across age groups, and there was a reduced total healthcare burden related to ED visits and hospitalization rates (overall, for DKA, and for hypoglycemia).
  • From a Canadian private payer perspective, FreeStyle systems are cost effective compared with SMBG for all peopleliving with diabetes.
  • Diabetic ketoacidosis (DKA) is associated with significant clinical and economic burden in T2D, thus resources that can help screen DKA in high risk populations (poorly controlled T2D, non-adherence to insulin, SGLT2 users) can reduce the burden of DKA on patients and the healthcare system.
  • Among people age ≥ 66 years with T2D using basal insulin, adoption of FreeStyle Libre Systems is associated with reductions in mean HbA1c levels and healthcare resource utilization.
  • A RWE study shows that average glucose and HbA1c displace a nonlinear and variable relationship.
  • Personalized HbA1c (pA1c) is superior to laboratory HbA1c at reflecting individualized average glycemia across all racial groups, potentially improving glycemic management in diabetes and reducing health disparities.
  • A multi-center observational logitudinal study showed mean HbA1c decreased by 1.0% after 12 months of starting CGM use in patients with T2D irrespective of insulin therapy.

CE/CME Programs